SCHEDULE: Vanguard Group Reports 0% Stake in Recursion Pharma
Schedule 13G Amendment
The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Recursion Pharmaceuticals Inc. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 4 to Schedule 13G for Recursion Pharmaceuticals Inc. Common Stock.
- The filing indicates that The Vanguard Group now beneficially owns 0.00 shares, representing 0% of the class.
- This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting an internal organizational change at The Vanguard Group, rather than a direct positive or negative statement on Recursion Pharmaceuticals Inc.'s performance or prospects.
Industry Context
StockSavvy.ai notes that such internal realignments by large asset managers like Vanguard are administrative and typically do not reflect a change in investment thesis regarding the underlying company, Recursion Pharmaceuticals Inc. The disaggregation of reporting among subsidiaries is a common practice for compliance and operational efficiency.
Stakeholder Impact
- Shareholders of Recursion Pharmaceuticals Inc. will observe a change in the reported beneficial ownership by The Vanguard Group, though the underlying investment by Vanguard's various funds may still exist, just reported under different entities.
- For Vanguard's clients, this reflects a change in the internal reporting structure of their investments.
Next Steps
- Certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
Key Dates
| Date | Description |
|---|---|
| January 12, 1998 | Date of SEC Release No. 34-39538, which provides guidance for disaggregated reporting. |
| January 12, 2026 | Date of The Vanguard Group, Inc.'s internal realignment. |
| March 13, 2026 | Date of event which required the filing of this statement. |
| March 27, 2026 | Date the Schedule 13G Amendment No. 4 was signed by The Vanguard Group. |
Keywords
Recursion Pharmaceuticals, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, internal realignment, common stock, investment adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.